Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
Authors:
Open Access
- 12 September 2021
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (9) , e002737
Abstract
Background: Chimeric antigen receptor (CAR) T cells have shown considerable promise as a personalized cellular immunotherapy against B cell malignancies. However, the complex and lengthy manufacturing processes involved in generating CAR T cell products ex vivo result in substantial production time delays and high costs. Furthermore, ex vivo expansion of T cells promotes cell differentiation that reduces their in vivo replicative capacity and longevity. Methods: Here, to overcome these limitations, CAR-T cells are engineered directly in vivo by administering a lentivirus expressing a mutant Sindbis envelope, coupled with a bispecific antibody binder that redirects the virus to CD3+ human T cells. Results: This redirected lentiviral system offers exceptional specificity and efficiency; a single dose of the virus delivered to immunodeficient mice engrafted with human peripheral blood mononuclear cells generates CD19-specific CAR-T cells that markedly control the growth of an aggressive pre-established xenograft B cell tumor. Conclusions: These findings underscore in vivo engineering of CAR-T cells as a promising approach for personalized cancer immunotherapy.Keywords
Funding Information
- National Science Foundation (DGE-1650116)
- NIDCR of the National Institutes of Health (F32DE026683)
- David and Lucile Packard Foundation (2013-39274)
- National Institutes of Health (5-R01-CA193140)
This publication has 55 references indexed in Scilit:
- Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulationJournal of Translational Medicine, 2010
- Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting TyrosinaseThe Journal of Immunology, 2010
- Targeted Transduction via CD4 by a Lentiviral Vector Uses a Clathrin-Mediated Entry PathwayJournal of Virology, 2009
- Engineering fusogenic molecules to achieve targeted transduction of enveloped lentiviral vectorsJournal of Biological Engineering, 2009
- A versatile targeting system with lentiviral vectors bearing the biotin‐adaptor peptideThe Journal of Gene Medicine, 2009
- Redirecting lentiviral vectors by insertion of integrin‐tageting peptides into envelope proteinsThe Journal of Gene Medicine, 2009
- Viral vectors: from virology to transgene expressionBritish Journal of Pharmacology, 2009
- Targeted gene delivery to CD117‐expressing cells in vivo with lentiviral vectors co‐displaying stem cell factor and a fusogenic moleculeBiotechnology and Bioengineering, 2009
- Cell Type-Specific Targeting with Surface-Engineered Lentiviral Vectors Co-displaying OKT3 Antibody and Fusogenic MoleculePharmaceutical Research, 2009
- Engineered lentivector targeting of dendritic cells for in vivo immunizationNature Biotechnology, 2008